1.33
-0.06 (-4.32%)
| Penutupan Terdahulu | 1.39 |
| Jumlah Dagangan | 1,317,162 |
| Harga / Buku (P/B) | 4.84 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.960 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.67% |
| Nisbah Semasa (MRQ) | 3.00 |
| Aliran Tunai Operasi (OCF TTM) | -15.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.19 M |
| Pulangan Atas Aset (ROA TTM) | -90.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -332.67% |
AISkor Stockmoo
| Nilai 30% | -0.5 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Masa 30% | -3.6 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Berita info | NA |
| Wang Pintar 20% | -2.6 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih -3.16% daripada saham dalam pemfailan 13F terkini: 25 pemegang menambah, 55 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -1.0% dari 31 Aug hingga 30 Oct 2026, 12.6 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. info | |
| Skor Akhir | -2.45 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | TuHURA Biosciences, Inc. | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HURA | - | - | - | 4.84 |
| TRML | 1 B | - | - | 4.76 |
| CTMX | - | - | - | 1.55 |
| GANX | - | - | - | 4.54 |
| PRTA | - | - | - | 1.56 |
| ZURA | - | - | - | 0.670 |
|
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 41.96% |
| % Dimiliki oleh Institusi | 8.43% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 13.83%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 25 | 1,172,612 |
| Berkurang | 55 | 3,348,265 |
| Baharu | 8 | 600,341 |
| Dijual habis | 18 | 513,423 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 6,203,722 | 12.6 |
| 15 Oct 2026 | 5,938,259 | 26.9 |
| 30 Sep 2026 | 6,096,015 | 28.4 |
| 15 Sep 2026 | 6,279,519 | 32.6 |
| 31 Aug 2026 | 6,267,797 | 27.9 |
| 14 Aug 2026 | 6,323,340 | 21.0 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended September 30, 2026, and provided a corporate… |
| 04 Nov 2026 | Yahoo Finance |
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in… |
| 03 Nov 2026 | Yahoo Finance |
HURA: First Look at IFx-2.0 Deep-Seated Tumors
By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH NOTE Interim Readout for IFx-2.0 Phase Ib/IIa Open-Label Study TuHURA (NASDAQ:HURA) presented first data from its IFx-2.0 Phase Ib/IIa study in deep-seated Merkel cell carcinoma (MCC) patients while attending the European Society… |
| 26 Oct 2026 | Yahoo Finance |
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting. Speaking duri… |
| 26 Oct 2026 | Yahoo Finance |
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy… |
| 13 Oct 2026 | Yahoo Finance |
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104 entitled… |
| 05 Oct 2026 | Yahoo Finance |
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled… |
| 14 Sep 2026 | Yahoo Finance |
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New… |
| 08 Sep 2026 | Yahoo Finance |
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C.… |
| 26 Aug 2026 | Yahoo Finance |
HURA: Milestone Progression Over Next 12 Months
By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On August 14 th , 2026, TuHURA Biosciences, Inc. (NASDAQ: HURA) reported 2Q:26 financial and operational results and filed its Form 10-Q with the SEC. There have been several updates since… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |